title: [Low-dosage ASA should not be given as primary prevention. The risk is greater than the benefit--also in high risk of cardiovascular disease].
authors.affiliation: Krokoms hälsocentral. jan.hakansson@jll.se
authors.forename: Jan
authors.initials: J
authors.lastname: Håkansson
authors.forename: Anders
authors.initials: A
authors.lastname: Hernborg
mesh_terms: D000367:Age Factors; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011322:Primary Prevention; D012307:Risk Factors; D055502:Secondary Prevention; D012737:Sex Factors
chemical_list: D005343:Fibrinolytic Agents; D001241:Aspirin
vernacular_title: Lågdos-ASA bör inte ges som primärprevention. Risken större än nyttan--också vid hög risk för hjärt-kärlsjukdom.